360° SearchNetwork Hot Spots Trends Time Series

Plavix

Type: Product

Name: Plavix

First reported May 24 2013 - Updated 5 hours ago - 1 reports

Is the Patent Cliff a Lethal Blow to Big Pharma?

A little over a year ago in this space, we called your attention to a developing situation in the pharmaceutical industry, as shown by the chart below that dramatically illustrates the arrival of the so-called "patent cliff" .Today, the results are in ... [Published Proactive Investors USA - May 24 2013]

Entities: Patent, Drugs, Big Pharma

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Falling can lead to brain injuries

To view our videos, you need toenable JavaScript. Learn how.install Adobe Flash 9 or above. Install now. Then come back here and refresh the page. According up to the CDC, nearly 75 percent of people over the age of who fall have injuries serious enough ... [Published YNN Rochester - May 24 2013]

Entities: Motrin, Coumadin, Plavix, Vitamin E

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Eli Lilly & Company

The 2013 Pharm Exec Top 50

Disruptive market change in the biopharmaceutical industry is a given—but individual company performance is rising to the occasion through efficient deployment of a still considerable inventory of product, process, and knowledge assets. If anything, uncertainty ... [Published Pharmaceutical Executive - May 22 2013]

Entities: Patent, Big Pharma, Eli Lilly & Company

First reported May 21 2013 - Updated May 21 2013 - 1 reports

French Autorité de la Concurrence Fines Sanofi €40.6 Million for Denigrating Competing Generics

" "May 21, 2013 | Skadden, Arps, Slate, Meagher & Flom LLP | Simon Baxter, Frederic Depoortere, Ingrid Vandenborre, James S. VenitOn May 14, 2013, the French Autorité de la Concurrence (Autorité) issued a decision imposing a fine of €40.6 million on ... [Published Skadden - May 21 2013]

Entities: Sanofi SA, Plavix, Clopidogrel, Aspirin

First reported May 20 2013 - Updated May 20 2013 - 1 reports

European Union

Sanofi May Get EU Double Whammy After French Fine For Hindering Entry Of Plavix Generics

Echoing the European Commission’s probe into whether drug companies blocked regional entry of cheaper generics, France’s Competition Authority has fined Sanofi €40.6 million for hindering domestic access to generic equivalents of its blockbuster clot-buster ... [Published The Rose Sheet - May 20 2013]

Entities: Plavix, Sanofi SA, European Union, European Commission, Drugs

First reported May 14 2013 - Updated May 15 2013 - 2 reports

Sanofi Fined $52.8 Million for Denigrating Copies of Plavix Drug

Sanofi (SAN), France’s largest drugmaker, was fined 40.6 million euros ($52.8 million) by the country’s competition regulator for trying to limit sales of generic versions of the company’s Plavix blood thinner.Sanofi denigrated the copies of the drug ... [Published BusinessWeek - May 14 2013]

Entities: Sanofi SA, Plavix, Drugs, blood thinner, Generic Version

First reported May 14 2013 - Updated May 15 2013 - 4 reports

Sanofi SA

Sanofi Fined for Discouraging Generic Plavix Prescriptions

French drugmaker Sanofi-Aventis was fined $52.6 million by the French competition authority Tuesday for marketing practices that discouraged sales of generic versions of the company’s blood thinner Plavix. ... [Published FDA News - May 15 2013]

Entities: Plavix, Sanofi SA, blood thinner

First reported May 14 2013 - Updated May 14 2013 - 6 reports

Sanofi fined in Plavix generics dispute

* Sanofi fined 40.6 million euros * Fine follows complaint filed by Teva Sante * Sanofi may appeal decision, shares down 0.6 percent (Adds details, Sanofi comments, shares) By Dominique Vidalon and NoÃ«lle Mennella PARIS, May 14 (Reuters) - The French ... [Published Sharenet - May 14 2013]

Entities: Sanofi SA, Plavix, Teva Pharmaceutical Industries Ltd, Stocks, Dominique Vidalon

First reported May 09 2013 - Updated May 09 2013 - 9 reports

Drug spending falls for first time in 55 years

Expiration of patents on blockbuster drugs such as Lipitor and Plavix lead to dip in drug spending in 2012 The amount of money Americans spend on prescription drugs fell for the first time in 55 years, according to a report from the IMS Institute of Healthcare ... [Published Chicago Tribune - May 09 2013]

Entities: Drugs, Lipitor, Patent, Plavix

First reported May 02 2013 - Updated May 02 2013 - 3 reports

Sanofi's net profit drops by 45% to Euro 1,004 million in Q1

Sanofi has suffered heavy setback during the first quarter ended March 2013 on account of loss of exclusivity of its major product during 2012. Its net sales declined by 5.3 per cent to Euro 8,059 million from Euro 8,511 million in the similar period ... [Published PharmaBiz - May 02 2013]

Entities: Sanofi SA, Declination, Net Profit, Aprovel, Plavix

First reported Apr 25 2013 - Updated Apr 25 2013 - 5 reports

New Bristol-Myers drug growth cushions plummeting Plavix sales

Bristol-Myers Squibb ($BMY) chose a good day to report its first-quarter results. AstraZeneca's ($AZN) declining sales and profits help blunt its own disappointments: earnings that dropped 44%, on a 27% decline in sales. Fortunately, the $3.83 billion ... [Published FiercePharma - Apr 25 2013]

Entities: Bristol-Myers Squibb Company, Plavix, Avapro, Drugs

First reported Apr 25 2013 - Updated Apr 25 2013 - 4 reports

Bristol Myers Profit Declines on Expired Patents; Matches Earnings Estimates (BMY)

Biopharmaceutical company, Bristol Myers Squibb Co. ( BMY ) saw a decline in earnings on Thursday, caused by the loss of sales from expired patents. Still, the company matched analysts earnings estimates for the first quarter.The New York, NY based company ... [Published Dividend.com - Apr 25 2013]

Entities: Bristol-Myers Squibb Company, Avalide, Avapro

Quotes

...Bipartisan Congressional Privacy Caucus – sent a letter to Larry Page which outlined eight questions for Google and asked for a response by June 14. "We are curious whether this new technology could infringe on the privacy of the average American" the letter read. Will Washington pass regulations on the new device before its general release next year? We shall see

Is the Patent Cliff a Lethal Blow to Big Pharma? [Published Proactive Investors USA - May 24 2013]

Pelitis said, "Make sure thresholds as you enter one room to another are even, putting night lights in the house."

Falling can lead to brain injuries [Published YNN Rochester - May 24 2013]

...It also may be instructive to note that during a , Mr. Mann stated "I believe AFREZZA could potentially even become the most significant medical product ever." It would be easy to dismiss this statement as hyperbole or the wishful musings of a corporate chieftain, but the speaker's extraordinary life story...

Pricing A Highly Probable Takeover Of MannKind [Published Seeking Alpha - May 22 2013]

...Christopher A Viehbacher, CEO of Sanofi, declared: "The appointment of these two new leaders will enable us to strengthen our growth platforms and ensure the success of our new products to deliver a sustainable future for our company. Peter is a proven leader with a strong track record in achieving ambitious commercial objectives. His most recent experience in Europe has prepared him well for driving growth in the rapidly evolving healthcare environment. Pascale's diversified experience in healthcare and acute commercial focus will be a great addition to Sanofi. I am confident that her expertise in diagnostics and medical technology will reinforce our mission as an integrated global healthcare company."

Sanofi announces management changes [Published Individual.com - May 21 2013]

More Content

sort by: Date \| Relevance
Coenzyme Q10 for Heart [Published EverydayHealth.com - 23 hours ago]
Is the Patent Cliff a Lethal Blow to Big Pharma? [Published Proactive Investors USA - May 24 2013]
Falling can lead to brain injuries [Published YNN Rochester - May 24 2013]
A survivor at 78, A.J. Foyt looking for an Indy... [Published Detroit Free Press - May 24 2013]
A look back at Sanofi's merger with Synthélabo [Published PMLive - May 24 2013]
Porter Novelli Assigned Comms Duties For Potent... [Published Holmes Report - May 23 2013]
New Oral Anticoagulants Markets [Published Zecco - May 22 2013]
The 2013 Pharm Exec Top 50 [Published Pharmaceutical Executive - May 22 2013]
Pricing A Highly Probable Takeover Of MannKind [Published Seeking Alpha - May 22 2013]
We Are About To Change Entertainment [Published AMD Zone - May 21 2013]
French Autorité de la Concurrence Fines Sanofi ... [Published Skadden - May 21 2013]
Bristol-Myers Squibb's Management Presents at U... [Published Seeking Alpha - May 21 2013]
A New Way to Open Clogged Arteries [Published Bioscience Technology Online - May 21 2013]
Sanofi announces management changes [Published Individual.com - May 21 2013]
Evaluating a new way to open clogged arteries [Published Medical Xpress - May 21 2013]
Evaluating a new way to open clogged arteries [Published MIT News feed - May 21 2013]
Med mal alleging woman should have remained in ... [Published The Southeast Texas Record - May 21 2013]
Teva Bets on Reformulating Old Drugs as Investo... [Published La Repubblica - May 20 2013]
Poll: Over One Million Seniors Have Problems Wi... [Published TheStreet.com - May 20 2013]
Sanofi reconsiders closure plans in Toulouse af... [Published PMLive - May 20 2013]
Sanofi May Get EU Double Whammy After French Fi... [Published The Rose Sheet - May 20 2013]
Bristol Myers: New Drugs Show Promise, Plavix P... [Published Trefis - May 17 2013]
Drug Discovery News: Facing the Patent Cliff He... [Published Baker Botts - May 17 2013]
Sanofi (France) Agrees to Reorganize Toulouse R... [Published BioSpace - May 17 2013]
Sanofi balks on jobs promises at R&D site in To... [Published FierceBiotech - May 17 2013]
Sanofi, French Government at Odds Over Fate of ... [Published Washington Post - May 17 2013]
US Embassy, USAID Will Attend 14th Conference o... [Published Hondurasweekly - May 17 2013]
Indian essential drug prices to fall "up to 80%" [Published Pharma Times - May 17 2013]
Crime rate drops [Published Kelowna Daily Courier - May 17 2013]
Sanofi Should Keep Toulouse Site, Government Re... [Published BusinessWeek - May 17 2013]

Blogs

sort by: Date \| Relevance
Evaluating a new way to open clogged arteries [Published MIT News feed - May 21 2013] Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments has drawbacks, including the risk of side effects.A ...
Using Price Transparency Data Within the Hospital [Published The Health Care Blog - May 17 2013] By David Halpert, MD Last week, CMS unilaterally released chargemaster data from 300 hospitals around the country. As David Dranove summed up well in his recent piece , this is an old hat. Yes, there are big variations in hospitals’ chargemasters. ...
New Resources to Find Affordable Medications [Published Prescription Access Litigation (PAL) Project - May 16 2013] As patients and consumers, we face more and more choices about our health care each year. We all support consumer empowerment in decisions about their care, but consumers don’t always have all the information they need to choose between different prescription ...
New Resources to Find Affordable Medications [Published Postscript - May 16 2013] As patients and consumers, we face more and more choices about our health care each year. We all support consumer empowerment in decisions about their care, but consumers don’t always have all the information they need to choose between different prescription ...
An Anticoagulant Antidote [Published In the Pipeline - May 09 2013] Here's a drug-discovery problem that you don't often have to think about. The anticoagulant field is a huge one, with Plavix, warfarin, and plenty of others jostling for a share of a huge market (both for patients to take themselves, and for hospital ...

Press Releases

sort by: Date \| Relevance
Study: Most on Blood Thinners Get Wrong Dose [Published CisionWire - English - Nov 28 2012]
Life Sciences Entrepreneurs S.L. annonce le pre... [Published PR Newswire - Nov 05 2012]
Il dispositivo WATCHMAN® di Boston Scientific p... [Published PR Newswire - Aug 27 2012]
WATCHMAN®, dispositif d'occlusion de l'appendic... [Published PR Newswire - Aug 27 2012]
WATCHMAN™-Implantat von Boston Scientific zum V... [Published PR Newswire - Aug 27 2012]